Committee advances bill to phase out DEHP in IV bags and tubing

A Senate health committee advanced legislation that would phase out intentionally added di(2‑ethylhexyl) phthalate (DEHP) from certain medical devices, saying the change would establish a consistent statewide standard for reducing patient exposure.

The amendment that rewrites the bill passed by voice vote and the full bill was moved and carried to the calendar. The sponsor told the committee the measure, as amended, would "phase out the use of DEHP in intravenous solution containers by 01/01/2030 and intravenous tubing by 01/01/2035," and would prohibit substitution with ortho‑phthalates, while including a delayed compliance pathway tied to FDA approval or manufacturing constraints.

"DEHP is a chemical, plasticizer... It's used in products like IV bags, but it can leach into fluids, deliver directly into a patient's bloodstream," the sponsor said, arguing the health risks, especially to vulnerable patients such as infants, warrant clear state standards.

Committee members offered brief support; no sustained opposition was recorded in the hearing. The amendment was moved and seconded, members voted in favor, and the committee reported the bill to the calendar with a recorded 9 ayes, chairman said.

If enacted, the law would set the statewide timeline for manufacturers and purchasers to transition to non‑DEHP containers and tubing; the amendment also included language intended to prevent manufacturers from substituting other ortho‑phthalates that may present similar risks.

The committee record shows the bill will now be placed on the legislative calendar for further consideration.